Core Insights - The article highlights the transformative opportunities in the internet healthcare industry driven by rapid advancements in artificial intelligence and the implementation of the Healthy China 2030 strategy [1][2][3] Group 1: Company Overview - Fangzhou Yunkang is recognized as a leading "AI + chronic disease management" service platform in China, establishing itself as an industry benchmark through innovative technology applications and a solid service system [1] - The company has developed a comprehensive health science popularization platform, "Fangzhou Yiliao," aimed at shifting patients from passive recognition to active management of their health [1] Group 2: Service and Technology Integration - Fangzhou Yiliao has upgraded its service model to an "AI + H2H" ecosystem, integrating AI technology throughout the health science popularization process [2] - The platform utilizes a self-developed large model to simplify complex pathological mechanisms into easily understandable content, enhancing user accessibility to health knowledge [2] Group 3: Achievements and Recognition - Fangzhou Yunkang has received multiple industry awards, including the "2025 Annual Social Responsibility Golden Bull Award" from China Securities Journal and recognition as a "Demonstration Case of Growth in Hong Kong Stocks" from China Fund News, reflecting strong market confidence in its development model and growth potential [3] - The company aims to continue deepening the integration of "AI + chronic disease management," focusing on delivering high-quality health science content and intelligent management services to enhance public health literacy [3]

Core Insights - The 2025 Health Technology and Science Popularization Conference focused on the theme "AI Leading a New Era of Health Science Popularization," bringing together experts and practitioners to discuss the integration of AI technology in health education and chronic disease management [1] Group 1: Company Overview - Fangzhou Yunkang has been deeply engaged in the chronic disease management sector, aiming to enhance patients' self-management capabilities and quality of life through technological means [2] - The company launched the chronic disease management health science popularization platform "Fangzhou Yiliao" in 2021, which aims to shift patients from a "passive understanding" to "active management" of their health [2] - The platform has served over 25 million users, with a total exposure of science popularization content exceeding 1.2 billion times and has produced over 30,000 compliant science popularization articles [2] Group 2: Technological Innovation - Fangzhou Yiliao completed an "AI + H2H" technology upgrade in 2025, integrating AI deeply into the health science popularization process to address common patient challenges [3] - The platform utilizes a self-developed large model to simplify complex medical concepts and enhance user engagement through a "full-scene human-machine collaboration" model [3] - Recent campaigns, such as "AI + Psoriasis Management" and "AI + Diabetes Management," have significantly increased content dissemination efficiency, attracting over one million viewers [3] Group 3: Content Integrity and Future Outlook - Fangzhou Yiliao maintains a rigorous content verification process, incorporating a four-tier safeguard mechanism to ensure the accuracy and reliability of health science content [4] - The recognition of Fangzhou Yiliao as the "Best Innovative Work" highlights the industry's acknowledgment of its AI-driven science popularization efforts [4] - The company aims to continue integrating chronic disease management practices with AI technology to enhance the reach and effectiveness of health education, contributing to the "Healthy China 2030" initiative [4]